ADDYY +2.2% Expansion ADDYY +2.2% Partnership ACLLF +3.5% Partnership ACDVF -1.7% Contract Loss ACDVF -1.7% Earnings Beat ACDVF -1.7% Earnings Beat ACDVF -1.7% Partnership ACDVF -1.7% Expansion ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Partnership ABBRF +33.1% Drill Results ABBRF +33.1% Drill Results ABBRF +33.1% Expansion ADDYY +2.2% Expansion ADDYY +2.2% Partnership ACLLF +3.5% Partnership ACDVF -1.7% Contract Loss ACDVF -1.7% Earnings Beat ACDVF -1.7% Earnings Beat ACDVF -1.7% Partnership ACDVF -1.7% Expansion ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Partnership ABBRF +33.1% Drill Results ABBRF +33.1% Drill Results ABBRF +33.1% Expansion ADDYY +2.2% Expansion ADDYY +2.2% Partnership ACLLF +3.5% Partnership ACDVF -1.7% Contract Loss ACDVF -1.7% Earnings Beat ACDVF -1.7% Earnings Beat ACDVF -1.7% Partnership ACDVF -1.7% Expansion ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Product Launch ABXXF +4.2% Partnership ABBRF +33.1% Drill Results ABBRF +33.1% Drill Results ABBRF +33.1% Expansion
StocksPulse BETA
Explore Pro Dashboard
CSL Ltd.

CSL Ltd.

CSLLY · OTCQX International · Complex biologicals, vaccines, plasma and plasma derived therapeutics · Australia
$50.95 -3.87%
Vol: 248,300 High: $52.20 Low: $50.85
78
Partnership
2d ago

Today, we announced an exclusive licencing agreement with Eli Lilly and Company granting certain rights to develop and commercialise clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody. CSL...

keywords
AI Reasoning

AI: Exclusive licensing agreement with major pharma company Eli Lilly for clazakizumab (anti-IL-6 monoclonal antibody). CSL retains rights for cardiovascular applications in ESKD patients. Strategic partnership with concrete therapeutic focus.

📕📕📕Free book alert! Visit https://lnkd.in/ees24d3h to download "More than a Patient" by Jodi Taub, who is both a #primaryimmunodeficiency patient and an experienced therapist who works with patients who have rare and chronic diseases. #CSL is sharing Jodi's book in honor of #RareDiseaseDay this mont...

0 0
2d ago LinkedIn

Getting sick once in a while is normal. But being sick on repeat, again and again, without answers, isn’t. For many people living with persistent infections, the experience can be exhausting, frustrating, and lonely. And far too often, it takes years to understand that these repeat infections might...

0 0
2d ago LinkedIn

CSL is the world’s only maker of antivenoms for native Australian species — a critical role in protecting public health and saving lives. Behind this achievement is a team of passionate people committed to science and impact. Join CSL and help us tackle global health challenges: https://bit.ly/40...

0 0
2d ago LinkedIn

Today, we announced an exclusive licencing agreement with Eli Lilly and Company granting certain rights to develop and commercialise clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody. CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardio...

0 0
2d ago LinkedIn

As we approach Rare Disease Day, we’re raising awareness of ANCA-associated vasculitis (AAV) — a rare autoimmune disease that causes inflammation in small blood vessels and can lead to serious organ damage. Because symptoms can vary widely and affect multiple organs, diagnosis can be complex and del...

0 0
2d ago LinkedIn

As we approach Rare Disease Day on February 28, learn more about hereditary angioedema (HAE), a rare condition that causes dangerous swelling attacks. https://lnkd.in/egYtJAWB #CSL #RareDiseaseDay #HereditaryAngioedema #HAEAwareness #KnowHAE

0 0
2d ago LinkedIn

As the need for advanced fibrinogen therapies grows, CSL teams are driving innovation that strengthens surgical care, trauma treatment and emergency medicine worldwide. Our work in fibrinogen science reflects the expertise and impact behind every product we deliver. Shape what’s possible in life sc...

0 0
2d ago LinkedIn

💙💚💜🩷Bright Colors and Zebra Stripes! 🦓 Rare Disease Day is February 28th but why were those colors selected? And how did rare disease patients adopt the zebra as an icon? https://bit.ly/4b3SrD4 #RareDiseaseDay #RareDiseases #CSL

0 0
2d ago LinkedIn

Flu season hits hardest when temperatures and humidity drop, which is why winter brings waves of illness across the globe. At CSL, we’re working to stay ahead of the virus with science that protects, adapts, and helps save lives. Click the link to learn more about our impact in fighting the flu: htt...

0 0
2d ago LinkedIn

CSL is the world’s only maker of antivenoms for many native venomous Australian species. Click the link to learn more about how we are serving a significant public health need: csl.com/impact #CSL #CSLImpactReport #Antivenom #Seqirus

0 0
2d ago LinkedIn

Signal Stats

Total
1
Avg Score
78
Hot
0
Posts
10

Company Info

ExchangeOTC
MarketplaceOTCQX International
SectorComplex biologicals, vaccines, plasma and plasma derived therapeutics
IndustryBiotechnology Research
CountryAustralia
LinkedIn Followers305,333
Employees23,248

Signal Types

Partnership 1
Pro Dashboard

Real-time alerts, watchlists, and price correlation stats.

Login with LinkedIn